Header Logo

Connection

WAYNE GOODMAN to Humans

Back to Details
This is a "connection" page, showing publications WAYNE GOODMAN has written about Humans.
WAYNE GOODMAN
Connection Strength
1.738
Humans
  1. Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders. Am J Psychiatry. 2025 Mar 01; 182(3):285-296.
    View in: PubMed
    Score: 0.026
  2. Deep Brain Stimulation for Obsessive-Compulsive Disorder: Optimal Stimulation Sites. Biol Psychiatry. 2024 Jul 15; 96(2):101-113.
    View in: PubMed
    Score: 0.024
  3. Randomized trial comparing standard versus light intensity parent training for anxious youth. Behav Res Ther. 2024 02; 173:104451.
    View in: PubMed
    Score: 0.024
  4. Attenuating side effects of deep brain stimulation in the bed nucleus of the stria terminalis for obsessive compulsive disorder using current-steering strategies. Brain Stimul. 2023 Mar-Apr; 16(2):650-652.
    View in: PubMed
    Score: 0.023
  5. Brain Imaging in Psychiatry: Time to Move From Regions of Interest and Interpretive Analyses to Connectomes and Predictive Modeling? Am J Psychiatry. 2023 01 01; 180(1):17-19.
    View in: PubMed
    Score: 0.023
  6. Obsessive Compulsive and Related Disorders. Psychiatr Clin North Am. 2023 03; 46(1):xiii-xv.
    View in: PubMed
    Score: 0.022
  7. Connectomic approaches to deep brain stimulation for OCD. Neuropsychopharmacology. 2022 03; 47(4):801-802.
    View in: PubMed
    Score: 0.021
  8. The prefrontal cortex and neurosurgical treatment for intractable OCD. Neuropsychopharmacology. 2022 01; 47(1):349-360.
    View in: PubMed
    Score: 0.020
  9. Response to: Optimizing DBS Stimulation Parameters in Obsessive-Compulsive Disorder. Neuromodulation. 2021 Feb; 24(2):400.
    View in: PubMed
    Score: 0.020
  10. Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. Am J Psychiatry. 2021 01 01; 178(1):17-29.
    View in: PubMed
    Score: 0.020
  11. Impact of the COVID-19 pandemic on exposure and response prevention outcomes in adults and youth with obsessive-compulsive disorder. Psychiatry Res. 2021 01; 295:113597.
    View in: PubMed
    Score: 0.019
  12. Moderators and predictors of response to deep transcranial magnetic stimulation for obsessive-compulsive disorder. J Psychiatr Res. 2021 04; 136:508-514.
    View in: PubMed
    Score: 0.019
  13. Little Doubt That CBT Works for Pediatric OCD. J Am Acad Child Adolesc Psychiatry. 2020 07; 59(7):785-787.
    View in: PubMed
    Score: 0.019
  14. Deep Brain Stimulation for Intractable Obsessive-Compulsive Disorder: Progress and Opportunities. Am J Psychiatry. 2020 03 01; 177(3):200-203.
    View in: PubMed
    Score: 0.018
  15. Psychiatric Diagnoses and Medications for Hurricane Harvey Sheltered Evacuees. Community Ment Health J. 2019 10; 55(7):1099-1102.
    View in: PubMed
    Score: 0.017
  16. Development and Psychometric Evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale Second Edition. J Am Acad Child Adolesc Psychiatry. 2019 01; 58(1):92-98.
    View in: PubMed
    Score: 0.017
  17. High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology. 2019 01; 44(2):390-398.
    View in: PubMed
    Score: 0.017
  18. Meeting the Mental Health Needs of Hurricane Harvey Evacuees. Am J Psychiatry. 2018 Jan 01; 175(1):13-14.
    View in: PubMed
    Score: 0.016
  19. Altered olfactory processing and increased insula activity in patients with obsessive-compulsive disorder: An fMRI study. Psychiatry Res Neuroimaging. 2017 Apr 30; 262:15-24.
    View in: PubMed
    Score: 0.015
  20. Switching between internally and externally focused attention in obsessive-compulsive disorder: Abnormal visual cortex activation and connectivity. Psychiatry Res Neuroimaging. 2017 Jul 30; 265:87-97.
    View in: PubMed
    Score: 0.014
  21. Neural correlates of emotional response inhibition in obsessive-compulsive disorder: A preliminary study. Psychiatry Res. 2015 Nov 30; 234(2):259-64.
    View in: PubMed
    Score: 0.014
  22. Obsessive-compulsive disorder. Psychiatr Clin North Am. 2014 Sep; 37(3):257-67.
    View in: PubMed
    Score: 0.013
  23. Obsessive compulsive and related disorders. Psychiatr Clin North Am. 2014 Sep; 37(3):xi-xii.
    View in: PubMed
    Score: 0.013
  24. Neuromodulation for obsessive-compulsive disorder. Neurotherapeutics. 2014 Jul; 11(3):485-95.
    View in: PubMed
    Score: 0.012
  25. The Persistence of Experience: Prior Attentional and Emotional State Affects Network Functioning in a Target Detection Task. Cereb Cortex. 2015 Sep; 25(9):3235-48.
    View in: PubMed
    Score: 0.012
  26. The anxiety severity interview for children and adolescents: an individualized repeated measure of anxiety severity. Clin Psychol Psychother. 2014 Nov-Dec; 21(6):525-35.
    View in: PubMed
    Score: 0.012
  27. History of psychosurgery: a psychiatrist's perspective. World Neurosurg. 2013 Sep-Oct; 80(3-4):S27.e1-16.
    View in: PubMed
    Score: 0.011
  28. Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD. Psychiatry Res. 2013 Feb 28; 205(3):253-61.
    View in: PubMed
    Score: 0.011
  29. Deep brain stimulation for intractable psychiatric disorders. Annu Rev Med. 2012; 63:511-24.
    View in: PubMed
    Score: 0.010
  30. Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Pediatr. 2012 Feb; 160(2):314-9.
    View in: PubMed
    Score: 0.010
  31. Electroconvulsive therapy in the spotlight. N Engl J Med. 2011 May 12; 364(19):1785-7.
    View in: PubMed
    Score: 0.010
  32. The role of avoidance in the phenomenology of obsessive-compulsive disorder. Compr Psychiatry. 2012 Feb; 53(2):187-94.
    View in: PubMed
    Score: 0.010
  33. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition. Psychol Assess. 2010 Jun; 22(2):223-32.
    View in: PubMed
    Score: 0.009
  34. Psychometric analysis of the Yale-Brown Obsessive-Compulsive Scale Second Edition Symptom Checklist. J Anxiety Disord. 2010 Aug; 24(6):650-6.
    View in: PubMed
    Score: 0.009
  35. Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 2010 Mar 15; 67(6):535-42.
    View in: PubMed
    Score: 0.009
  36. Quality of life in children and adolescents with obsessive-compulsive disorder: base rates, parent-child agreement, and clinical correlates. Soc Psychiatry Psychiatr Epidemiol. 2009 Nov; 44(11):935-42.
    View in: PubMed
    Score: 0.009
  37. Deep brain stimulation in psychiatry: concentrating on the road ahead. Biol Psychiatry. 2009 Feb 15; 65(4):263-6.
    View in: PubMed
    Score: 0.009
  38. Concurrent validity of the Yale-Brown Obsessive-Compulsive Scale-Symptom Checklist. J Clin Psychol. 2008 Dec; 64(12):1338-51.
    View in: PubMed
    Score: 0.008
  39. Bridging bench and practice: translational research for schizophrenia and other psychotic disorders. Neuropsychopharmacology. 2009 Jan; 34(1):204-12.
    View in: PubMed
    Score: 0.008
  40. Insight in pediatric obsessive-compulsive disorder: associations with clinical presentation. Psychiatry Res. 2008 Aug 15; 160(2):212-20.
    View in: PubMed
    Score: 0.008
  41. Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2008 May; 47(5):583-592.
    View in: PubMed
    Score: 0.008
  42. SSRI adverse events: how to monitor and manage. Int Rev Psychiatry. 2008 Apr; 20(2):203-8.
    View in: PubMed
    Score: 0.008
  43. Avoiding deep brain stimulation failures in Tourette syndrome. J Neurol Neurosurg Psychiatry. 2008 Feb; 79(2):111-2.
    View in: PubMed
    Score: 0.008
  44. Where does obsessive-compulsive disorder belong in DSM-V? Depress Anxiety. 2008; 25(4):336-47.
    View in: PubMed
    Score: 0.008
  45. Cognitive-behavioral therapy for obsessive-compulsive disorder: a non-randomized comparison of intensive and weekly approaches. J Anxiety Disord. 2008 Oct; 22(7):1146-58.
    View in: PubMed
    Score: 0.008
  46. Recognition and treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2007 Dec; 68(12):e30.
    View in: PubMed
    Score: 0.008
  47. Symptom dimensions and cognitive-behavioural therapy outcome for pediatric obsessive-compulsive disorder. Acta Psychiatr Scand. 2008 Jan; 117(1):67-75.
    View in: PubMed
    Score: 0.008
  48. Sleep-related problems in pediatric obsessive-compulsive disorder. J Anxiety Disord. 2008 Jun; 22(5):877-85.
    View in: PubMed
    Score: 0.008
  49. Florida Obsessive-Compulsive Inventory: development, reliability, and validity. J Clin Psychol. 2007 Sep; 63(9):851-9.
    View in: PubMed
    Score: 0.008
  50. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007 Jul; 22(4):230-7.
    View in: PubMed
    Score: 0.008
  51. Associations between miscellaneous symptoms and symptom dimensions: an examination of pediatric obsessive-compulsive disorder. Behav Res Ther. 2007 Nov; 45(11):2593-603.
    View in: PubMed
    Score: 0.008
  52. Clinical features of children and adolescents with obsessive-compulsive disorder and hoarding symptoms. Compr Psychiatry. 2007 Jul-Aug; 48(4):313-8.
    View in: PubMed
    Score: 0.008
  53. Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approaches. J Am Acad Child Adolesc Psychiatry. 2007 Apr; 46(4):469-478.
    View in: PubMed
    Score: 0.008
  54. Sequential cognitive-behavioral therapy for children with obsessive-compulsive disorder with an inadequate medication response: a case series of five patients. Depress Anxiety. 2007; 24(6):375-81.
    View in: PubMed
    Score: 0.007
  55. Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology (Berl). 2007 Mar; 191(1):87-96.
    View in: PubMed
    Score: 0.007
  56. Factor-analytic study of the Yale Global Tic Severity Scale. Psychiatry Res. 2007 Jan 15; 149(1-3):231-7.
    View in: PubMed
    Score: 0.007
  57. Cognitive-behavioral therapy for PANDAS-related obsessive-compulsive disorder: findings from a preliminary waitlist controlled open trial. J Am Acad Child Adolesc Psychiatry. 2006 Oct; 45(10):1171-8.
    View in: PubMed
    Score: 0.007
  58. Deep brain stimulation in the internal capsule and nucleus accumbens region: responses observed during active and sham programming. J Neurol Neurosurg Psychiatry. 2007 Mar; 78(3):310-4.
    View in: PubMed
    Score: 0.007
  59. Obsessive-compulsive disorder in Tourette syndrome. J Child Neurol. 2006 Aug; 21(8):704-14.
    View in: PubMed
    Score: 0.007
  60. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. J Psychiatr Res. 2007 Apr-Jun; 41(3-4):332-7.
    View in: PubMed
    Score: 0.007
  61. Immunology of obsessive-compulsive disorder. Psychiatr Clin North Am. 2006 Jun; 29(2):445-69.
    View in: PubMed
    Score: 0.007
  62. Panic and fear induced by deep brain stimulation. J Neurol Neurosurg Psychiatry. 2006 Mar; 77(3):410-2.
    View in: PubMed
    Score: 0.007
  63. The children's Yale-Brown obsessive-compulsive scale: psychometric properties of child- and parent-report formats. J Anxiety Disord. 2006; 20(8):1055-70.
    View in: PubMed
    Score: 0.007
  64. The neurocircuitry of obsessive-compulsive disorder and disgust. Prog Neuropsychopharmacol Biol Psychiatry. 2006 May; 30(3):389-99.
    View in: PubMed
    Score: 0.007
  65. Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety. 2006; 23(7):429-33.
    View in: PubMed
    Score: 0.007
  66. Reliability and validity of the Yale Global Tic Severity Scale. Psychol Assess. 2005 Dec; 17(4):486-91.
    View in: PubMed
    Score: 0.007
  67. Hope and coping in family members of patients with obsessive-compulsive disorder. J Anxiety Disord. 2006; 20(5):614-29.
    View in: PubMed
    Score: 0.007
  68. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005 Aug; 87(2-3):161-7.
    View in: PubMed
    Score: 0.007
  69. Factor analytic study of the Children's Yale-Brown Obsessive-Compulsive Scale. J Clin Child Adolesc Psychol. 2005 Jun; 34(2):312-9.
    View in: PubMed
    Score: 0.007
  70. Effects of Stepped Cognitive Behavioral Therapy on Child Depressive and Externalizing Symptoms in Autistic Children With Anxiety. Am J Intellect Dev Disabil. 2025 May 01; 130(3):228-243.
    View in: PubMed
    Score: 0.007
  71. Psychometric properties of the Spanish Yale-Brown Obsessive-Compulsive Scale - Second Edition. Psychiatry Res. 2025 Jun; 348:116456.
    View in: PubMed
    Score: 0.007
  72. Computational sensitivity evaluation of ultrasound neuromodulation resolution to brain tissue sound speed with robust beamforming. Sci Rep. 2025 Apr 02; 15(1):11251.
    View in: PubMed
    Score: 0.007
  73. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005 Apr-Jun; 17(2):71-5.
    View in: PubMed
    Score: 0.007
  74. High intensity approaches to exposure and response prevention for obsessive-compulsive disorder. Behav Brain Res. 2025 Mar 12; 481:115427.
    View in: PubMed
    Score: 0.006
  75. Cost-effectiveness analysis of deep brain stimulation versus treatment as usual for treatment-resistant obsessive-compulsive disorder. J Neurosurg. 2025 May 01; 142(5):1225-1234.
    View in: PubMed
    Score: 0.006
  76. Yale-Brown Obsessive Compulsive Scale: the dimensional structure revisited. Depress Anxiety. 2005; 22(1):28-35.
    View in: PubMed
    Score: 0.006
  77. Aperiodic spectral slope tracks the effects of brain state on saliency responses in the human auditory cortex. Sci Rep. 2024 12 28; 14(1):30751.
    View in: PubMed
    Score: 0.006
  78. Challenges and opportunities of acquiring cortical recordings for chronic adaptive deep brain stimulation. Nat Biomed Eng. 2025 May; 9(5):606-617.
    View in: PubMed
    Score: 0.006
  79. Problematic Substance Use in Depressed Youth: Associations with Suicidal Ideation and Suicide Attempt History. J Dual Diagn. 2025 Jan-Mar; 21(1):35-48.
    View in: PubMed
    Score: 0.006
  80. Cognitive-behavioral therapy for obsessive-compulsive disorder: review of treatment techniques. J Psychosoc Nurs Ment Health Serv. 2004 Dec; 42(12):44-51.
    View in: PubMed
    Score: 0.006
  81. Psychometric evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale. Psychiatry Res. 2004 Nov 30; 129(1):91-8.
    View in: PubMed
    Score: 0.006
  82. Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
    View in: PubMed
    Score: 0.006
  83. Psychometric Properties of the Yale-Brown Obsessive Compulsive Scale-II Self-Report. J Psychiatr Pract. 2024 Nov 01; 30(6):421-427.
    View in: PubMed
    Score: 0.006
  84. Parent perceptions of various treatment approaches for PANS and PANDAS. J Affect Disord. 2025 Jan 15; 369:1215-1222.
    View in: PubMed
    Score: 0.006
  85. Misconceptions Among Mental Health Treatment Providers About OCD and PTSD. Behav Ther. 2025 05; 56(3):470-486.
    View in: PubMed
    Score: 0.006
  86. Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Dec; 9(12):1239-1248.
    View in: PubMed
    Score: 0.006
  87. What's in a "smile?" Intra-operative observations of contralateral smiles induced by deep brain stimulation. Neurocase. 2004 Aug; 10(4):271-9.
    View in: PubMed
    Score: 0.006
  88. Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
    View in: PubMed
    Score: 0.006
  89. Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nat Med. 2024 Oct; 30(10):3004-3014.
    View in: PubMed
    Score: 0.006
  90. Obsessive-Compulsive Disorder in Children and Adolescents. Annu Rev Clin Psychol. 2024 Jul; 20(1):355-380.
    View in: PubMed
    Score: 0.006
  91. Pediatric Treatment-Resistant Obsessive Compulsive Disorder: Treatment Options and Challenges. Paediatr Drugs. 2024 Jul; 26(4):397-409.
    View in: PubMed
    Score: 0.006
  92. A Low-Intensity Transcranial Focused Ultrasound Parameter Exploration Study of the Ventral Capsule/Ventral Striatum. Neuromodulation. 2025 Jan; 28(1):146-154.
    View in: PubMed
    Score: 0.006
  93. Stereo-Electroencephalography-Guided Network Neuromodulation for Psychiatric Disorders: The Neurophysiology Monitoring Unit. Oper Neurosurg (Hagerstown). 2024 Sep 01; 27(3):329-336.
    View in: PubMed
    Score: 0.006
  94. Co-occurring PTSD in intensive OCD treatment: Impact on treatment trajectory vs. response. J Affect Disord. 2024 05 15; 353:109-116.
    View in: PubMed
    Score: 0.006
  95. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004 Mar 01; 55(5):553-5.
    View in: PubMed
    Score: 0.006
  96. The clinical presentation of major depressive disorder in youth with co-occurring obsessive-compulsive disorder. J Affect Disord. 2024 03 15; 349:349-357.
    View in: PubMed
    Score: 0.006
  97. Efficacy and acceptability of cognitive-behavioral therapy and serotonin reuptake inhibitors for pediatric obsessive-compulsive disorder: a network meta-analysis. J Child Psychol Psychiatry. 2024 05; 65(5):594-609.
    View in: PubMed
    Score: 0.006
  98. Perceived worsening of obsessive-compulsive disorder symptoms after childbirth in women and men: An understudied phenomenon. Bull Menninger Clin. 2024; 88(1):48-60.
    View in: PubMed
    Score: 0.006
  99. Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics. Biol Psychiatry. 2004 Jan 01; 55(1):61-8.
    View in: PubMed
    Score: 0.006
  100. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry. 2004; 65 Suppl 13:8-13.
    View in: PubMed
    Score: 0.006
  101. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2004; 65 Suppl 14:6-10.
    View in: PubMed
    Score: 0.006
  102. Further psychometric properties of the Tourette's Disorder Scale-Parent Rated version (TODS-PR). Child Psychiatry Hum Dev. 2004; 35(2):107-20.
    View in: PubMed
    Score: 0.006
  103. Stereo-EEG-guided network modulation for psychiatric disorders: Surgical considerations. Brain Stimul. 2023 Nov-Dec; 16(6):1792-1798.
    View in: PubMed
    Score: 0.006
  104. Alterations in attentional processing in youth with misophonia: A phenotypical cross-comparison with anxiety patients. J Affect Disord. 2024 02 15; 347:429-436.
    View in: PubMed
    Score: 0.006
  105. Depressive symptoms during deep transcranial magnetic stimulation or sham treatment for obsessive-compulsive disorder. J Affect Disord. 2024 01 01; 344:466-472.
    View in: PubMed
    Score: 0.006
  106. Predictors and Moderators of Treatment Outcomes for Anxious Children Randomized to Computer-Assisted Cognitive Behavioral Therapy or Standard Community Care. J Child Adolesc Psychopharmacol. 2023 10; 33(8):316-324.
    View in: PubMed
    Score: 0.006
  107. Brain activation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry. 2003 Oct 01; 54(7):751-6.
    View in: PubMed
    Score: 0.006
  108. Family Accommodation in Children and Adolescents With Misophonia. Behav Ther. 2024 05; 55(3):595-604.
    View in: PubMed
    Score: 0.006
  109. Parent-Led Cognitive Behavioral Teletherapy for Anxiety in Autistic Youth: A Randomized Trial Comparing Two Levels of Therapist Support. Behav Ther. 2024 05; 55(3):499-512.
    View in: PubMed
    Score: 0.006
  110. Computational modeling and minimization of unintended neuronal excitation in a LIFU stimulation. Sci Rep. 2023 08 17; 13(1):13403.
    View in: PubMed
    Score: 0.006
  111. Modeling Suicidality with Multimodal Impulsivity Characterization in Participants with Mental Health Disorder. Behav Neurol. 2023; 2023:8552180.
    View in: PubMed
    Score: 0.006
  112. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. J Affect Disord. 2023 10 15; 339:584-592.
    View in: PubMed
    Score: 0.006
  113. Participant perceptions of changes in psychosocial domains following participation in an adaptive deep brain stimulation trial. Brain Stimul. 2023 Jul-Aug; 16(4):990-998.
    View in: PubMed
    Score: 0.006
  114. Measuring misophonia in youth: A psychometric evaluation of child and parent measures. J Affect Disord. 2023 10 01; 338:180-186.
    View in: PubMed
    Score: 0.006
  115. Future directions in psychiatric neurosurgery: Proceedings of the 2022 American Society for Stereotactic and Functional Neurosurgery meeting on surgical neuromodulation for psychiatric disorders. Brain Stimul. 2023 May-Jun; 16(3):867-878.
    View in: PubMed
    Score: 0.006
  116. Dual-Target Deep Brain Stimulation for Obsessive-Compulsive Disorder and Tourette Syndrome. Biol Psychiatry. 2023 06 01; 93(11):e53-e55.
    View in: PubMed
    Score: 0.006
  117. Examining the Relationship Between Anxiety Severity and Autism-Related Challenges During Cognitive Behavioral Therapy for Children with Autism. J Autism Dev Disord. 2024 May; 54(5):1849-1856.
    View in: PubMed
    Score: 0.006
  118. Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review. Pharmacoeconomics. 2023 05; 41(5):499-527.
    View in: PubMed
    Score: 0.006
  119. Decoding Depression Severity From Intracranial Neural Activity. Biol Psychiatry. 2023 09 15; 94(6):445-453.
    View in: PubMed
    Score: 0.006
  120. Tractography-Based Modeling Explains Treatment Outcomes in Patients Undergoing Deep Brain Stimulation for Obsessive-Compulsive Disorder. Biol Psychiatry. 2024 Jul 15; 96(2):95-100.
    View in: PubMed
    Score: 0.006
  121. COVID-19-related intrusive thoughts and associated ritualistic behaviors. Bull Menninger Clin. 2023; 87(3):225-249.
    View in: PubMed
    Score: 0.006
  122. Anger Outbursts in Youth with ASD and Anxiety: Phenomenology and Relationship with Family Accommodation. Child Psychiatry Hum Dev. 2024 Oct; 55(5):1259-1268.
    View in: PubMed
    Score: 0.006
  123. Clinical characteristics, impairment, and psychiatric morbidity in 102 youth with misophonia. J Affect Disord. 2023 03 01; 324:395-402.
    View in: PubMed
    Score: 0.006
  124. Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder. Psychiatr Clin North Am. 2023 03; 46(1):167-180.
    View in: PubMed
    Score: 0.006
  125. The Relationship Between Adverse Childhood Experiences, Symptom Severity, Negative Thinking, Comorbidity, and Treatment Response in Youth with Obsessive-Compulsive Disorder. Child Psychiatry Hum Dev. 2024 Oct; 55(5):1201-1210.
    View in: PubMed
    Score: 0.006
  126. Neurosurgical Approaches for Treatment-Resistant Obsessive-Compulsive Disorder. Psychiatr Clin North Am. 2023 03; 46(1):121-132.
    View in: PubMed
    Score: 0.006
  127. Intraoperative valence testing to adjudicate between ventral capsule/ventral striatum and bed nucleus of the stria terminalis target selection in deep brain stimulation for obsessive-compulsive disorder. J Neurosurg. 2023 08 01; 139(2):442-450.
    View in: PubMed
    Score: 0.006
  128. Stepped-Care Cognitive Behavioral Therapy in Children on the Autism Spectrum with Co-occurring Anxiety. J Autism Dev Disord. 2024 Jan; 54(1):93-108.
    View in: PubMed
    Score: 0.006
  129. Periodic Artifact Removal With Applications to Deep Brain Stimulation. IEEE Trans Neural Syst Rehabil Eng. 2022; 30:2692-2699.
    View in: PubMed
    Score: 0.006
  130. Perceptions of various treatment approaches for adults and children with misophonia. J Affect Disord. 2022 11 01; 316:76-82.
    View in: PubMed
    Score: 0.005
  131. Cost-effectiveness analysis of radiosurgical capsulotomy versus treatment as usual for treatment-resistant obsessive-compulsive disorder. J Neurosurg. 2023 02 01; 138(2):347-357.
    View in: PubMed
    Score: 0.005
  132. EMvelop stimulation: minimally invasive deep brain stimulation using temporally interfering electromagnetic waves. J Neural Eng. 2022 07 04; 19(4).
    View in: PubMed
    Score: 0.005
  133. Optimizing Obsessive-Compulsive Symptom Measurement With the Yale-Brown Obsessive-Compulsive Scales-Second Edition. J Psychiatr Pract. 2022 07 01; 28(4):294-309.
    View in: PubMed
    Score: 0.005
  134. Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol. 2002 Jun; 5(2):141-5.
    View in: PubMed
    Score: 0.005
  135. Provider perceptions of telehealth and in-person exposure and response prevention for obsessive-compulsive disorder. Psychiatry Res. 2022 07; 313:114610.
    View in: PubMed
    Score: 0.005
  136. Primary Outcomes for Adults Receiving the Unified Protocol after Hurricane Harvey in an Integrated Healthcare Setting. Community Ment Health J. 2022 11; 58(8):1522-1534.
    View in: PubMed
    Score: 0.005
  137. Imaging versus electrographic connectivity in human mood-related fronto-temporal networks. Brain Stimul. 2022 May-Jun; 15(3):554-565.
    View in: PubMed
    Score: 0.005
  138. Honeycomb: a template for reproducible psychophysiological tasks for clinic, laboratory, and home use. Braz J Psychiatry. 2022 Mar-Abr; 44(2):147-155.
    View in: PubMed
    Score: 0.005
  139. Brief, parent-led, transdiagnostic cognitive-behavioral teletherapy for youth with emotional problems related to the COVID-19 pandemic. J Affect Disord. 2022 Mar 15; 301:130-137.
    View in: PubMed
    Score: 0.005
  140. Family Accommodation of Symptoms in Adults With Obsessive-Compulsive Disorder: Factor Structure and Usefulness of the Family Accommodation Scale for OCD-Patient Version. J Psychiatr Pract. 2022 01 06; 28(1):36-47.
    View in: PubMed
    Score: 0.005
  141. Genetics of childhood disorders: XXXIV. Autoimmune disorders, part 7: D8/17 reactivity as an immunological marker of susceptibility to neuropsychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2002 Jan; 41(1):98-100.
    View in: PubMed
    Score: 0.005
  142. Anxiety in Angelman Syndrome. Am J Intellect Dev Disabil. 2022 01 01; 127(1):1-10.
    View in: PubMed
    Score: 0.005
  143. Cost-effectiveness analysis of deep transcranial magnetic stimulation relative to evidence-based strategies for treatment-refractory obsessive-compulsive disorder. J Psychiatr Res. 2022 02; 146:50-54.
    View in: PubMed
    Score: 0.005
  144. Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder. Nat Med. 2021 12; 27(12):2154-2164.
    View in: PubMed
    Score: 0.005
  145. Deep Brain Stimulation for Depression Informed by Intracranial Recordings. Biol Psychiatry. 2022 08 01; 92(3):246-251.
    View in: PubMed
    Score: 0.005
  146. Progress toward analysis of D8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder. J Neuroimmunol. 2001 Nov 01; 120(1-2):146-51.
    View in: PubMed
    Score: 0.005
  147. In Reply: A Novel Framework for Network-Targeted Neuropsychiatric Deep Brain Stimulation. Neurosurgery. 2021 10 13; 89(5):E283.
    View in: PubMed
    Score: 0.005
  148. Obsessive-Compulsive Disorder During the COVID-19 Pandemic: a Systematic Review. Curr Psychiatry Rep. 2021 10 06; 23(11):71.
    View in: PubMed
    Score: 0.005
  149. Obsessive compulsive disorder: is there an association with childhood streptococcal infections and altered immune function? Semin Clin Neuropsychiatry. 2001 Oct; 6(4):266-76.
    View in: PubMed
    Score: 0.005
  150. Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder. J Am Acad Child Adolesc Psychiatry. 2022 04; 61(4):495-507.
    View in: PubMed
    Score: 0.005
  151. The psychobiology of obsessive-compulsive disorder: how important is the role of disgust? Curr Psychiatry Rep. 2001 Aug; 3(4):281-7.
    View in: PubMed
    Score: 0.005
  152. A Novel Framework for Network-Targeted Neuropsychiatric Deep Brain Stimulation. Neurosurgery. 2021 07 15; 89(2):E116-E121.
    View in: PubMed
    Score: 0.005
  153. Uncovering biomarkers during therapeutic neuromodulation with PARRM: Period-based Artifact Reconstruction and Removal Method. Cell Rep Methods. 2021 06 21; 1(2).
    View in: PubMed
    Score: 0.005
  154. Addressing the mental health needs of learners and nonlearners in an academic medical center during COVID-19. Bull Menninger Clin. 2021; 85(3):283-297.
    View in: PubMed
    Score: 0.005
  155. Defining functional brain networks underlying obsessive-compulsive disorder (OCD) using treatment-induced neuroimaging changes: a systematic review of the literature. J Neurol Neurosurg Psychiatry. 2021 07; 92(7):776-786.
    View in: PubMed
    Score: 0.005
  156. Perceptions of Deep Brain Stimulation for Adolescents with Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol. 2021 03; 31(2):109-117.
    View in: PubMed
    Score: 0.005
  157. The Relationship of Family Accommodation with Pediatric Anxiety Severity: Meta-analytic Findings and Child, Family and Methodological Moderators. Child Psychiatry Hum Dev. 2021 02; 52(1):1-14.
    View in: PubMed
    Score: 0.005
  158. Family accommodation in Chinese individuals with obsessive-compulsive disorder. Psych J. 2021 Apr; 10(2):295-304.
    View in: PubMed
    Score: 0.005
  159. Age moderated-anxiety mediation for multimodal treatment outcome among children with obsessive-compulsive disorder: An evaluation with correspondence analysis. J Affect Disord. 2021 03 01; 282:766-775.
    View in: PubMed
    Score: 0.005
  160. Neural correlates of cognitive behavioral therapy response in youth with negative valence disorders: A systematic review of the literature. J Affect Disord. 2021 03 01; 282:1288-1307.
    View in: PubMed
    Score: 0.005
  161. The Impact of Comorbidity on Cognitive-Behavioral Therapy Response in Youth with Anxiety and Autism Spectrum Disorder. Child Psychiatry Hum Dev. 2020 08; 51(4):625-635.
    View in: PubMed
    Score: 0.005
  162. Deep transcranial magnetic stimulation for obsessive compulsive disorder. Expert Rev Neurother. 2020 10; 20(10):1029-1036.
    View in: PubMed
    Score: 0.005
  163. Neurostimulation for treatment-resistant posttraumatic stress disorder: an update on neurocircuitry and therapeutic targets. J Neurosurg. 2021 06 01; 134(6):1715-1723.
    View in: PubMed
    Score: 0.005
  164. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology. 2020 09; 45(10):1656-1663.
    View in: PubMed
    Score: 0.005
  165. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
    View in: PubMed
    Score: 0.005
  166. Parent-led Behavioral Intervention for a Treatment-refusing Adult With Obsessive-Compulsive Disorder With Poor Insight and Extreme Family Accommodation. J Psychiatr Pract. 2020 03; 26(2):149-152.
    View in: PubMed
    Score: 0.005
  167. Serious negative consequences associated with exposure and response prevention for obsessive-compulsive disorder: A survey of therapist attitudes and experiences. Depress Anxiety. 2020 05; 37(5):418-428.
    View in: PubMed
    Score: 0.005
  168. Stability of subclinical obsessive compulsive disorder in college students. Depress Anxiety. 2000; 11(4):180-2.
    View in: PubMed
    Score: 0.005
  169. Improving long term patient outcomes from deep brain stimulation for treatment-refractory obsessive-compulsive disorder. Expert Rev Neurother. 2020 01; 20(1):95-107.
    View in: PubMed
    Score: 0.005
  170. Development and psychometric evaluation of the Mandarin Chinese version of the Yale-Brown Obsessive-Compulsive Scale - Second Edition. Braz J Psychiatry. 2019 Nov-Dec; 41(6):494-498.
    View in: PubMed
    Score: 0.005
  171. Cost-Effectiveness of Treatment Alternatives for Treatment-Refractory Pediatric Obsessive-Compulsive Disorder. J Anxiety Disord. 2020 01; 69:102151.
    View in: PubMed
    Score: 0.005
  172. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
    View in: PubMed
    Score: 0.004
  173. Device Removal Following Brain Implant Research. Neuron. 2019 09 04; 103(5):759-761.
    View in: PubMed
    Score: 0.004
  174. The Centrality of Doubting and Checking in the Network Structure of Obsessive-Compulsive Symptom Dimensions in Youth. J Am Acad Child Adolesc Psychiatry. 2020 07; 59(7):880-889.
    View in: PubMed
    Score: 0.004
  175. Parents' Perceptions of Internalizing and Externalizing Features in Childhood OCD. Child Psychiatry Hum Dev. 2019 08; 50(4):692-701.
    View in: PubMed
    Score: 0.004
  176. Predictors of treatment outcome for youth receiving intensive residential treatment for obsessive-compulsive disorder (OCD). Cogn Behav Ther. 2020 07; 49(4):294-306.
    View in: PubMed
    Score: 0.004
  177. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry. 1999 Jun 01; 45(11):1440-6.
    View in: PubMed
    Score: 0.004
  178. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 11 01; 176(11):931-938.
    View in: PubMed
    Score: 0.004
  179. Chinese Therapists' Beliefs About Exposure Therapy for Anxiety and Obsessive-Compulsive Disorders. J Psychiatr Pract. 2019 05; 25(3):179-185.
    View in: PubMed
    Score: 0.004
  180. Incidence and clinical correlates of anger attacks in Chinese patients with obsessive-compulsive disorder. J Zhejiang Univ Sci B. 2019 Apr.; 20(4):363-370.
    View in: PubMed
    Score: 0.004
  181. Clinicians' perspectives of interfering behaviors in the treatment of anxiety and obsessive-compulsive disorders in adults and children. Cogn Behav Ther. 2020 01; 49(1):81-96.
    View in: PubMed
    Score: 0.004
  182. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry. 1999; 60 Suppl 18:27-32.
    View in: PubMed
    Score: 0.004
  183. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018 12 28; 18(1):82-84.
    View in: PubMed
    Score: 0.004
  184. Functional neural mechanisms of sensory phenomena in obsessive-compulsive disorder. J Psychiatr Res. 2019 02; 109:68-75.
    View in: PubMed
    Score: 0.004
  185. Evidence of prefrontal hyperactivation to food-cue reversal learning in adolescents with anorexia nervosa. Behav Res Ther. 2018 12; 111:36-43.
    View in: PubMed
    Score: 0.004
  186. Pharmacological risk factors associated with hospital readmission rates in a psychiatric cohort identified using prescriptome data mining. BMC Med Inform Decis Mak. 2018 09 14; 18(Suppl 3):79.
    View in: PubMed
    Score: 0.004
  187. Habenular connectivity may predict treatment response in depressed psychiatric inpatients. J Affect Disord. 2019 01 01; 242:211-219.
    View in: PubMed
    Score: 0.004
  188. Cognitive Behavioral Therapy for Childhood Anxiety Disorders: a Review of Recent Advances. Curr Psychiatry Rep. 2018 07 28; 20(8):65.
    View in: PubMed
    Score: 0.004
  189. Continued access to investigational brain implants. Nat Rev Neurosci. 2018 06; 19(6):317-318.
    View in: PubMed
    Score: 0.004
  190. Politically-focused intrusive thoughts and associated ritualistic behaviors in a community sample. J Anxiety Disord. 2018 05; 56:35-42.
    View in: PubMed
    Score: 0.004
  191. Impact of the 2016 US presidential election on OCD symptom presentation: A case illustration. J Clin Psychol. 2018 05; 74(5):750-754.
    View in: PubMed
    Score: 0.004
  192. Charting the road forward in psychiatric neurosurgery: proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders. J Neurol Neurosurg Psychiatry. 2018 08; 89(8):886-896.
    View in: PubMed
    Score: 0.004
  193. Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness. Hum Brain Mapp. 2017 12; 38(12):6068-6082.
    View in: PubMed
    Score: 0.004
  194. Neural correlates of affective and non-affective cognition in obsessive compulsive disorder: A meta-analysis of functional imaging studies. Eur Psychiatry. 2017 10; 46:25-32.
    View in: PubMed
    Score: 0.004
  195. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017 05 01; 74(5):501-510.
    View in: PubMed
    Score: 0.004
  196. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997; 33(1):17-22.
    View in: PubMed
    Score: 0.004
  197. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry. 1997; 58 Suppl 5:32-49.
    View in: PubMed
    Score: 0.004
  198. Six-Nine Year Follow-Up of Deep Brain Stimulation for Obsessive-Compulsive Disorder. PLoS One. 2016; 11(12):e0167875.
    View in: PubMed
    Score: 0.004
  199. Recent developments in neurobiology of obsessive-compulsive disorder. J Clin Psychiatry. 1996 Oct; 57(10):492-503.
    View in: PubMed
    Score: 0.004
  200. Safety and efficacy of electroconvulsive therapy for depression in the presence of deep brain stimulation in obsessive-compulsive disorder. J Clin Psychiatry. 2016 05; 77(5):689-90.
    View in: PubMed
    Score: 0.004
  201. Resting-state functional connectivity of the human habenula in healthy individuals: Associations with subclinical depression. Hum Brain Mapp. 2016 07; 37(7):2369-84.
    View in: PubMed
    Score: 0.004
  202. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996 Mar; 11(1):21-9.
    View in: PubMed
    Score: 0.004
  203. Human habenula segmentation using myelin content. Neuroimage. 2016 Apr 15; 130:145-156.
    View in: PubMed
    Score: 0.003
  204. Subclinical obsessive-compulsive disorder in college students. Depress Anxiety. 1996-1997; 4(5):233-6.
    View in: PubMed
    Score: 0.003
  205. Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. J Psychiatr Res. 2015 Dec; 71:140-7.
    View in: PubMed
    Score: 0.003
  206. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec; 45(16):3571-80.
    View in: PubMed
    Score: 0.003
  207. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry. 1995 Aug 01; 38(3):138-49.
    View in: PubMed
    Score: 0.003
  208. Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response. PLoS One. 2015; 10(7):e0133591.
    View in: PubMed
    Score: 0.003
  209. Testing the disgust conditioning theory of food-avoidance in adolescents with recent onset anorexia nervosa. Behav Res Ther. 2015 Aug; 71:131-8.
    View in: PubMed
    Score: 0.003
  210. Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline. Int J Neurosci. 2015; 125(7):475-85.
    View in: PubMed
    Score: 0.003
  211. Who qualifies for deep brain stimulation for OCD? Data from a naturalistic clinical sample. J Neuropsychiatry Clin Neurosci. 2014; 26(1):81-6.
    View in: PubMed
    Score: 0.003
  212. Surgical neuroanatomy and programming in deep brain stimulation for obsessive compulsive disorder. Neuromodulation. 2014 Jun; 17(4):312-9; discussion 319.
    View in: PubMed
    Score: 0.003
  213. Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther. 2013 Dec; 51(12):823-9.
    View in: PubMed
    Score: 0.003
  214. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry. 1993 Jun; 54 Suppl:16-26.
    View in: PubMed
    Score: 0.003
  215. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jun; 74(6):e527-32.
    View in: PubMed
    Score: 0.003
  216. Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013 Aug; 30(8):716-22.
    View in: PubMed
    Score: 0.003
  217. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013 Jan; 70(1):85-94.
    View in: PubMed
    Score: 0.003
  218. The relationship between insight and control in obsessive-compulsive disorder: implications for the insanity defense. Bull Am Acad Psychiatry Law. 1993; 21(2):245-52.
    View in: PubMed
    Score: 0.003
  219. Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am. 1992 Dec; 15(4):861-9.
    View in: PubMed
    Score: 0.003
  220. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol. 1992 Jun; 7 Suppl 1:35-8.
    View in: PubMed
    Score: 0.003
  221. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry. 1992 Apr; 53 Suppl:29-37.
    View in: PubMed
    Score: 0.003
  222. Psychopharmacology of obsessive-compulsive disorder in Tourette syndrome. Adv Neurol. 1992; 58:283-91.
    View in: PubMed
    Score: 0.003
  223. Rebound symptoms following battery depletion in the NIH OCD DBS cohort: clinical and reimbursement issues. Brain Stimul. 2012 Oct; 5(4):599-604.
    View in: PubMed
    Score: 0.003
  224. Current treatment approaches to obsessive-compulsive disorder. Arch Psychiatr Nurs. 1991 Oct; 5(5):299-306.
    View in: PubMed
    Score: 0.003
  225. Cerebral laterality, perception of emotion, and treatment response in obsessive-compulsive disorder. Biol Psychiatry. 1991 May 01; 29(9):900-8.
    View in: PubMed
    Score: 0.003
  226. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord. 1990 Dec; 20(4):537-43.
    View in: PubMed
    Score: 0.002
  227. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010 Dec 01; 68(11):1073-6.
    View in: PubMed
    Score: 0.002
  228. Refining clinical judgment of treatment outcome in obsessive-compulsive disorder. Psychiatry Res. 2011 Feb 28; 185(3):394-401.
    View in: PubMed
    Score: 0.002
  229. A case of mania following deep brain stimulation for obsessive compulsive disorder. Stereotact Funct Neurosurg. 2010; 88(5):322-8.
    View in: PubMed
    Score: 0.002
  230. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry. 1990 Aug; 51 Suppl:36-43; discussion 55-8.
    View in: PubMed
    Score: 0.002
  231. Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry. 2010 Aug; 71(8):e1-e21.
    View in: PubMed
    Score: 0.002
  232. Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry. 2010 Aug; 71(8):1040-6.
    View in: PubMed
    Score: 0.002
  233. Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res. 2010 Aug 15; 178(3):467-74.
    View in: PubMed
    Score: 0.002
  234. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010 Jun; 27(6):507-27.
    View in: PubMed
    Score: 0.002
  235. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990 Jun; 47(6):577-85.
    View in: PubMed
    Score: 0.002
  236. Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. Neuroimage. 2011 Jan; 54 Suppl 1:S247-55.
    View in: PubMed
    Score: 0.002
  237. Lack of benefit of accumbens/capsular deep brain stimulation in a patient with both tics and obsessive-compulsive disorder. Neurocase. 2010 Aug; 16(4):321-30.
    View in: PubMed
    Score: 0.002
  238. Cognitive behavioral therapy plus motivational interviewing improves outcome for pediatric obsessive-compulsive disorder: a preliminary study. Cogn Behav Ther. 2010; 39(1):24-7.
    View in: PubMed
    Score: 0.002
  239. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989 Nov; 46(11):1012-6.
    View in: PubMed
    Score: 0.002
  240. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989 Nov; 46(11):1006-11.
    View in: PubMed
    Score: 0.002
  241. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010 Feb; 121(1-2):175-9.
    View in: PubMed
    Score: 0.002
  242. Children's Florida Obsessive Compulsive Inventory: psychometric properties and feasibility of a self-report measure of obsessive-compulsive symptoms in youth. Child Psychiatry Hum Dev. 2009 Sep; 40(3):467-83.
    View in: PubMed
    Score: 0.002
  243. Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder. Depress Anxiety. 2009; 26(1):E23-5.
    View in: PubMed
    Score: 0.002
  244. Deep brain stimulation for refractory obsessive-compulsive disorder. Front Biosci (Landmark Ed). 2009 01 01; 14(5):1880-90.
    View in: PubMed
    Score: 0.002
  245. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989 Jan; 46(1):36-44.
    View in: PubMed
    Score: 0.002
  246. Fluvoxamine as an antiobsessional agent. Psychopharmacol Bull. 1989; 25(1):31-5.
    View in: PubMed
    Score: 0.002
  247. Effects of serotonergic agonists on neuroendocrine responses of rhesus monkeys and patients with depression and anxiety disorders. Psychopharmacol Ser. 1989; 7:94-104.
    View in: PubMed
    Score: 0.002
  248. NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders. Neuropsychopharmacology. 2009 Jan; 34(1):229-43.
    View in: PubMed
    Score: 0.002
  249. Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2008 Jul; 47(7):763-772.
    View in: PubMed
    Score: 0.002
  250. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010 Jan; 15(1):64-79.
    View in: PubMed
    Score: 0.002
  251. Further psychometric analysis of the Florida Obsessive-Compulsive Inventory. J Anxiety Disord. 2009 Jan; 23(1):124-9.
    View in: PubMed
    Score: 0.002
  252. Associations between miscellaneous symptoms and symptom dimensions in adults with obsessive-compulsive disorder. Anxiety Stress Coping. 2008 Apr; 21(2):199-212.
    View in: PubMed
    Score: 0.002
  253. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.002
  254. Convergent and discriminant validity of the Children's Yale-Brown Obsessive Compulsive Scale-Symptom Checklist. J Anxiety Disord. 2008 Dec; 22(8):1369-76.
    View in: PubMed
    Score: 0.002
  255. Obsessive-compulsive disorder in youth with and without a chronic tic disorder. Depress Anxiety. 2008; 25(9):761-7.
    View in: PubMed
    Score: 0.002
  256. Clinical features associated with treatment-resistant pediatric obsessive-compulsive disorder. Compr Psychiatry. 2008 Jan-Feb; 49(1):35-42.
    View in: PubMed
    Score: 0.002
  257. A measure of functional impairment in youth with Tourette's syndrome. J Pediatr Psychol. 2007 Sep; 32(8):950-9.
    View in: PubMed
    Score: 0.002
  258. Family accommodation in pediatric obsessive-compulsive disorder. J Clin Child Adolesc Psychol. 2007 Apr-Jun; 36(2):207-16.
    View in: PubMed
    Score: 0.002
  259. Quality of life in youth with Tourette's syndrome and chronic tic disorder. J Clin Child Adolesc Psychol. 2007 Apr-Jun; 36(2):217-27.
    View in: PubMed
    Score: 0.002
  260. Further psychometric examination of the Tourette's Disorder Scales. Child Psychiatry Hum Dev. 2007 Aug; 38(2):89-98.
    View in: PubMed
    Score: 0.002
  261. Relationship of movements and behaviors to Group A Streptococcus infections in elementary school children. Biol Psychiatry. 2007 Feb 01; 61(3):279-84.
    View in: PubMed
    Score: 0.002
  262. Peer victimization in children with obsessive-compulsive disorder: relations with symptoms of psychopathology. J Clin Child Adolesc Psychol. 2006 Sep; 35(3):446-55.
    View in: PubMed
    Score: 0.002
  263. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov; 31(11):2384-93.
    View in: PubMed
    Score: 0.002
  264. Lessons learned in deep brain stimulation for movement and neuropsychiatric disorders. CNS Spectr. 2006 Jul; 11(7):521-36.
    View in: PubMed
    Score: 0.002
  265. Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry. 1986 Jul; 143(7):900-3.
    View in: PubMed
    Score: 0.002
  266. Long-term habituation of the smile response with deep brain stimulation. Neurocase. 2006 Jun; 12(3):191-6.
    View in: PubMed
    Score: 0.002
  267. Cognitive-behavioral treatment for obsessive-compulsive disorder in an elderly male with concurrent medical constraints. Am J Geriatr Psychiatry. 2006 Apr; 14(4):380-1.
    View in: PubMed
    Score: 0.002
  268. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. J Clin Psychiatry. 1985 Oct; 46(10 Pt 2):6-24.
    View in: PubMed
    Score: 0.002
  269. Reliability and validity of the Child Behavior Checklist Obsessive-Compulsive Scale. J Anxiety Disord. 2006; 20(4):473-85.
    View in: PubMed
    Score: 0.002
  270. Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res. 2005 Jul 15; 76(2-3):309-16.
    View in: PubMed
    Score: 0.002
  271. Assessment of pediatric obsessive-compulsive disorder: a critical review of current methodology. Child Psychiatry Hum Dev. 2005; 36(2):195-214.
    View in: PubMed
    Score: 0.002
  272. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry. 2004 Jun; 65(6):742-9.
    View in: PubMed
    Score: 0.002
  273. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 Jun; 64(6):640-7.
    View in: PubMed
    Score: 0.001
  274. Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Sep; 15(3):159-75.
    View in: PubMed
    Score: 0.001
  275. Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry. 2002 Feb; 159(2):263-8.
    View in: PubMed
    Score: 0.001
  276. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001 Feb; 21(1):46-52.
    View in: PubMed
    Score: 0.001
  277. The cognitive-affective neuroscience of obsessive-compulsive disorder. Curr Psychiatry Rep. 2000 Aug; 2(4):341-6.
    View in: PubMed
    Score: 0.001
  278. On defining Sydenham's chorea: where do we draw the line? Biol Psychiatry. 2000 May 15; 47(10):851-7.
    View in: PubMed
    Score: 0.001
  279. Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores. Am J Med Genet. 1999 Dec 15; 88(6):669-75.
    View in: PubMed
    Score: 0.001
  280. Cerebrospinal fluid dynorphin A[1-8] and beta-endorphin levels in Tourette's syndrome are unaltered. Biol Psychiatry. 1999 Jun 01; 45(11):1527-8.
    View in: PubMed
    Score: 0.001
  281. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry. 1999 May; 60(5):346-51; quiz 352.
    View in: PubMed
    Score: 0.001
  282. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res. 1999 Mar 22; 85(3):225-40.
    View in: PubMed
    Score: 0.001
  283. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology. 1999 Jan; 24(1):1-24.
    View in: PubMed
    Score: 0.001
  284. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997 Sep; 154(9):1293-5.
    View in: PubMed
    Score: 0.001
  285. Symptoms of obsessive-compulsive disorder. Am J Psychiatry. 1997 Jul; 154(7):911-7.
    View in: PubMed
    Score: 0.001
  286. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997 Jun; 36(6):844-52.
    View in: PubMed
    Score: 0.001
  287. Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry. 1997 May 01; 41(9):949-54.
    View in: PubMed
    Score: 0.001
  288. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry. 1997 Mar; 154(3):402-7.
    View in: PubMed
    Score: 0.001
  289. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry. 1997 Jan 01; 41(1):117-21.
    View in: PubMed
    Score: 0.001
  290. High doses of sertraline for treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1996 Sep; 153(9):1232-3.
    View in: PubMed
    Score: 0.001
  291. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996 May 01; 39(9):776-83.
    View in: PubMed
    Score: 0.001
  292. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995 Dec; 152(12):1812-4.
    View in: PubMed
    Score: 0.001
  293. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry. 1995 Jul 15; 38(2):74-85.
    View in: PubMed
    Score: 0.001
  294. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995 May; 152(5):772-7.
    View in: PubMed
    Score: 0.001
  295. Family accommodation in obsessive-compulsive disorder. Am J Psychiatry. 1995 Mar; 152(3):441-3.
    View in: PubMed
    Score: 0.001
  296. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995 Feb; 12(1):73-86.
    View in: PubMed
    Score: 0.001
  297. A family study of obsessive-compulsive disorder. Am J Psychiatry. 1995 Jan; 152(1):76-84.
    View in: PubMed
    Score: 0.001
  298. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry. 1995 Jan; 152(1):90-6.
    View in: PubMed
    Score: 0.001
  299. Effects of tryptophan depletion in panic disorder. Biol Psychiatry. 1994 Dec 01; 36(11):775-7.
    View in: PubMed
    Score: 0.001
  300. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry. 1994 Oct; 51(10):782-92.
    View in: PubMed
    Score: 0.001
  301. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994 Jul; 51(7):559-67.
    View in: PubMed
    Score: 0.001
  302. "Just right" perceptions associated with compulsive behavior in Tourette's syndrome. Am J Psychiatry. 1994 May; 151(5):675-80.
    View in: PubMed
    Score: 0.001
  303. Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry. 1994 Apr; 164(4):469-73.
    View in: PubMed
    Score: 0.001
  304. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr; 51(4):302-8.
    View in: PubMed
    Score: 0.001
  305. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994 Apr; 51(4):309-17.
    View in: PubMed
    Score: 0.001
  306. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry. 1994 Mar; 55 Suppl:24-31.
    View in: PubMed
    Score: 0.001
  307. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994 Feb; 151(2):289.
    View in: PubMed
    Score: 0.001
  308. The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology. 1994; 19(8):723-49.
    View in: PubMed
    Score: 0.001
  309. Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety. 1994-1995; 1(5):208-15.
    View in: PubMed
    Score: 0.001
  310. Inpatient treatment of patients with severe obsessive-compulsive disorder. Hosp Community Psychiatry. 1993 Dec; 44(12):1150-4.
    View in: PubMed
    Score: 0.001
  311. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am. 1993 Dec; 16(4):749-66.
    View in: PubMed
    Score: 0.001
  312. The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol. 1993 Nov; 8 Suppl 2:79-82.
    View in: PubMed
    Score: 0.001
  313. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol. 1993 Oct; 13(5):354-8.
    View in: PubMed
    Score: 0.001
  314. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 1993 Aug; 48(2):119-33.
    View in: PubMed
    Score: 0.001
  315. The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry. 1993 May; 26 Suppl 1:24-9.
    View in: PubMed
    Score: 0.001
  316. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993 Apr; 150(4):647-9.
    View in: PubMed
    Score: 0.001
  317. Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry. 1993 Apr 01; 33(7):547-50.
    View in: PubMed
    Score: 0.001
  318. Acute exacerbation of body dysmorphic disorder during tryptophan depletion. Am J Psychiatry. 1992 Oct; 149(10):1406-7.
    View in: PubMed
    Score: 0.001
  319. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992 Jul; 31(4):746-50.
    View in: PubMed
    Score: 0.001
  320. The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry. 1992 Apr; 53 Suppl:17-28.
    View in: PubMed
    Score: 0.001
  321. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991 Jun; 11(3):175-84.
    View in: PubMed
    Score: 0.001
  322. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry. 1990 Nov; 157:762-5.
    View in: PubMed
    Score: 0.001
  323. Low CSF 5HIAA and obsessions of violence: report of two cases. Psychiatry Res. 1990 Jul; 33(1):95-9.
    View in: PubMed
    Score: 0.001
  324. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990 May; 147(5):652-4.
    View in: PubMed
    Score: 0.001
  325. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. J Clin Psychiatry. 1990 Apr; 51 Suppl:44-50; discussion 51-2.
    View in: PubMed
    Score: 0.001
  326. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull. 1990; 26(1):54-9.
    View in: PubMed
    Score: 0.001
  327. Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(4):459-72.
    View in: PubMed
    Score: 0.001
  328. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990; 26(3):279-84.
    View in: PubMed
    Score: 0.001
  329. Pathophysiology of obsessive-compulsive disorder. Am J Psychiatry. 1989 Oct; 146(10):1350-1.
    View in: PubMed
    Score: 0.001
  330. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988 Feb; 45(2):177-85.
    View in: PubMed
    Score: 0.001
  331. Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry. 1988 Jan; 45(1):43-52.
    View in: PubMed
    Score: 0.000
  332. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987 Aug; 144(8):1030-6.
    View in: PubMed
    Score: 0.000
  333. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry. 1987 Aug; 144(8):1059-61.
    View in: PubMed
    Score: 0.000
  334. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology (Berl). 1987; 93(3):308-13.
    View in: PubMed
    Score: 0.000
  335. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl). 1987; 92(1):14-24.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.